Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 3:2023:3555418.
doi: 10.1155/2023/3555418. eCollection 2023.

Salivary Biomarkers: Noninvasive Ways for Diagnosis of Parkinson's Disease

Sanaz Salaramoli  1   2 , Hamid Reza Joshaghani  3 , Seyed Isaac Hashemy  2
Affiliations
Review

Salivary Biomarkers: Noninvasive Ways for Diagnosis of Parkinson's Disease

Sanaz Salaramoli et al. Neurol Res Int. .

Abstract

Finding reliable biomarkers has a crucial role in Parkinson's disease (PD) assessments. Saliva is a bodily fluid, which might be used as a source of biomarkers for PD. Our article has reviewed several publications on salivary proteins in PD patients and their potential as biomarkers. We find out that α-Syn's proportion in oligomeric form is higher in PD patients' saliva, which is potent to use as a biomarker for PD. The salivary concentration of DJ-1 and alpha-amylase is lower in PD patients. Also, substance P level is more moderate in PD patients. Although salivary flow rate is decreased in PD patients, high levels of heme oxygenase and acetylcholinesterase might be used as noninvasive biomarkers. Salivary miRNAs (miR-153, miR-223, miR-874, and miR-145-3p) are novel diagnostic biomarkers that should be given more attention.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References

    1. Pringsheim T., Jette N., Frolkis A. The prevalence of parkinson disease: a systematic review and meta-analysis (p03. 067) Movement Disorders . 2013;29 doi: 10.1002/mds.25945. - DOI - PubMed
    1. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. Journal of Neurochemistry . 2016;139:318–324. doi: 10.1111/jnc.13691. - DOI - PubMed
    1. Salaramoli S. Bio-synthesized selenium nanoparticles ameliorate brain oxidative stress in parkinson disease rat models. Metabolic Brain Disease . 2023;2023 doi: 10.1007/s11011-023-01222-6. - DOI - PubMed
    1. Salaramoli S., Joshaghani H., Hashemy S. I. Selenium effects on oxidative stress-induced calcium signaling pathways in Parkinson’s disease. Indian Journal of Clinical Biochemistry . 2022;37(3):257–266. doi: 10.1007/s12291-022-01031-1. - DOI - PMC - PubMed
    1. Ouchi Y., Yoshikawa E., Sekine Y., et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Annals of Neurology . 2005;57(2):168–175. doi: 10.1002/ana.20338. - DOI - PubMed

LinkOut - more resources